drugset / Trial / NCT05763550

To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Herpetic Neuralgia

NCT05763550

Phase 2 Completed 331 enrolled Haisco Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

Investigate the efficacy and safety of HSK16149 capsules in Chinese herpetic Neuralgia following 4 weeks treatment in comparison to pregabalin.

Timeline

Start
2023-02-27
Primary completion
2023-06-22
Completion
2023-08-07

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK16149 Unknown 20 mg Oral
Subject HSK16149 Unknown 40 mg Oral
Comparator Pregabalin Small molecule 150 mg Oral

Indications